$5.70 1.6%
MNKD Stock Price vs. AI Score (Last 150 days)
Data gathered: July 13

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Mannkind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.

Price $5.70
Target Price Sign up
Volume 2,120,000
Market Cap $1.55B
Year Range $3.25 - $5.7
Dividend Yield 0%
PE Ratio 142.5
Revenue per Employee $602,017
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2465M28M38M11M15M0.000
Q4 '2353M28M25M1.4M6.9M0.004
Q3 '2351M28M23M1.7M5.7M0.010
Q2 '2341M31M10M-5.3M2.7M-0.020
Q1 '2337M30M6.8M-9.8M-6.3M-0.040

Insider Transactions View All

Thomson David filed to sell 873,616 shares at $4.7.
May 21 '24
Binder Steven B. filed to sell 1,114,553 shares at $4.7.
May 21 '24
Thomson David filed to sell 783,446 shares at $4.3.
May 14 '24
Binder Steven B. filed to sell 845,967 shares at $4.3.
May 14 '24
Castagna Michael filed to sell 2,148,665 shares at $4.
December 15 '23

What is the Market Cap of Mannkind?

The Market Cap of Mannkind is $1.55B.

What is Mannkind's PE Ratio?

As of today, Mannkind's PE (Price to Earnings) ratio is 142.5.

How Many People Work at Mannkind?

As of our latest update, Mannkind employed approximately 349 people worldwide. However, it's important to note that Mannkind's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Mannkind's revenue per employee?

$602,017. To calculate Mannkind's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Mannkind?

Currently, the price of one share of Mannkind stock is $5.70.

How can I analyze the MNKD stock price chart for investment decisions?

The MNKD stock price chart above provides a comprehensive visual representation of Mannkind's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Mannkind shares. Our platform offers an up-to-date MNKD stock price chart, along with technical data analysis and alternative data insights.

Does MNKD offer dividends to its shareholders?

As of our latest update, Mannkind (MNKD) does not offer dividends to its shareholders. Investors interested in Mannkind should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Mannkind?

Some of the similar stocks of Mannkind are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.